Industry

New Drug Application filing anticipated based on positive data from interim analysis WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a statistically … [Read more…]

– Carbon is developing a novel parvovirus-based vector platform with demonstrated in-vivo tissue specificity, increased cargo capacity, and minimal natural neutralizing immunity; widens patient applicability and may enable gene therapy re-administration – Carbon’s lead candidate, CGT-001, targets lung tissue with demonstrated upper airway tissue tropism and repeatable dosing in gold-standard cystic fibrosis models – Financing … [Read more…]

MUNICH–(BUSINESS WIRE)–$BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022. Frank H. Laukien, PhD, President and CEO of Bruker Corporation, commented: “Our differentiated high-value scientific instruments and … [Read more…]

Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation today announced its investment of $6 million in Carbon Biosciences to support the company‘s preclinical research into an innovative … [Read more…]

FARMINGTON HILLS, Mich.–(BUSINESS WIRE)–Humanetics announced today that mg-sensor GmbH, specialists in the design and development of high-quality sensors, data acquisition and calibration services, is officially joining the Humanetics group. This partnership is another milestone as Humanetics brings to life its vision to provide fully integrated solutions with hardware, software, IoT and sensor technologies, that will … [Read more…]

CLEVELAND, Ohio–(BUSINESS WIRE)–$ATHX–Athersys, Inc. (Nasdaq: ATHX) today announced the Company’s slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET. As previously announced, in connection with the Company’s cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from ten to … [Read more…]

Survey of 12,850 people demonstrates the significant contribution of over-65s; report makes three-point recommendations to further improve intergenerational solidarity. NYON, Switzerland–(BUSINESS WIRE)–Edwards Lifesciences today published ‘Unifying Generations: Building the Pathway to Intergenerational Solidarity’ – a report, based on a survey of 12,850 Europeans across generations, that demonstrates the need to change perceptions of the value … [Read more…]

Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design Collaboration leverages Iktos’ capabilities in machine learning and AI and Zealand expertise in peptide drug discovery PARIS–(BUSINESS WIRE)–Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), … [Read more…]

Pharma and healthcare experts Dr Donna Lockhart and Greg Whelan join with newly created roles of Head of Medicines and Group Sales Director as business progresses LONDON–(BUSINESS WIRE)–#appointments–SpectrumX, a UK-based healthcare and pharmaceutical company, is pleased to announce it has strengthened its senior management team with Dr Donna Lockhart joining as Head of Medicines consultant … [Read more…]

EpiSwitch CiRT® is a first-of-its-kind precision medicine test that predicts a patient’s likely response to widely used Immune Checkpoint Inhibitor (ICI) therapies. The test has shown high sensitivity (93%), specificity (82%), accuracy (85%), and NPV (93%) across 15 cancer indications where ICI treatments are approved. The simple clinical blood test is now also available to … [Read more…]